Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 + Sintilimab vs interferon in adjuvant acral melanoma
CTR20200170Phase 3Terminated
- Sponsor
- Innovent Biologics
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310, sintilimab in melanoma, sponsored by Innovent Biologics. Started Feb 2020; status: terminated.
02
Drugs
IBI310sintilimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20200170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200170.